WHO South East Asia Regional - Immunization Technical Advisory Group (SEAR-ITAG)

Report of the Seventh Meeting
SEAR-ITAG

New Delhi, India, 7 to 10 June 2016
# Table of contents

<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table of contents</td>
<td>ii</td>
</tr>
<tr>
<td>Acronyms</td>
<td>iii</td>
</tr>
<tr>
<td>Introduction</td>
<td>1</td>
</tr>
<tr>
<td>Objectives</td>
<td>2</td>
</tr>
<tr>
<td>Conclusions and Recommendations</td>
<td>3</td>
</tr>
<tr>
<td>National Immunization Technical Advisory Groups (NITAGs)</td>
<td>3</td>
</tr>
<tr>
<td>SEAR Vaccine Action Plan</td>
<td>3</td>
</tr>
<tr>
<td>Equity</td>
<td>4</td>
</tr>
<tr>
<td>Immunization Legislation</td>
<td>4</td>
</tr>
<tr>
<td>Immunization Financing</td>
<td>5</td>
</tr>
<tr>
<td>Polio Eradication</td>
<td>7</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>9</td>
</tr>
<tr>
<td>Maternal and Neonatal Tetanus Elimination (MNTE)</td>
<td>10</td>
</tr>
<tr>
<td>Measles Elimination and Rubella/CRS Control</td>
<td>12</td>
</tr>
<tr>
<td>Data Quality</td>
<td>14</td>
</tr>
<tr>
<td>Vaccine Quality and Management</td>
<td>15</td>
</tr>
<tr>
<td>Adverse Events Following Immunization (AEFI)</td>
<td>16</td>
</tr>
<tr>
<td>New and Underutilized Vaccines Introduction (NUVI)</td>
<td>16</td>
</tr>
<tr>
<td>Way Forward</td>
<td>17</td>
</tr>
<tr>
<td>Annex 1: MEETING AGENDA</td>
<td>18</td>
</tr>
<tr>
<td>Annex 2: LIST OF PARTICIPANTS</td>
<td>19</td>
</tr>
</tbody>
</table>
ACRONYMS

AEFI  adverse events following immunization  
AFP  acute flaccid paralysis  
AI  appreciative inquiry  
ATAP  access to affordable pricing  
bOPV  Bivalent Oral Polio Vaccine  
CTC  controlled temperature chain  
FDA  Food and Drug Administration  
GAP  Global Action Plan  
GHSS  Global Health Sector Strategy  
GPEI  Global Polio Eradication Initiative  
GRISP  Global Routine Immunization Strategies and Practices  
GVAP  Global Vaccine Action Plan  
HBR  home-based records  
IEC  Information Education and Communication  
IPV  inactivated polio virus  
ITAG  Immunization Technical Advisory Group  
JRF  Joint Reporting Form  
LB  live births  
MNCH  Maternal, New-born and Child Health  
MNTE  Maternal and Neonatal Tetanus Elimination  
MOV  missed opportunities for vaccination  
MRCV  measles and rubella containing vaccine  
MRCV2  two-dose measles and rubella containing vaccine  
NITAG  National Immunization Technical Advisory Group  
NRA  National Regulatory Authority  
NUVI  New and Under-utilized Vaccines  
OPV  Oral Polio Vaccine  
OPV3  three-dose Oral Polio Vaccine  
PCV  pneumococcal conjugate vaccine  
PQ  pre-qualified  
RCCPE  Regional Commission for the Certification of Poliomyelitis Eradication  
RI  routine immunization  
RVAP  Regional Vaccine Action Plan  
RVC  South-East Asia Regional Verification Commission for Measles Elimination and Rubella/CRS Control  
SAGE  Strategic Advisory Group of Experts on Immunization  
SDG  Sustainable Development Goals  
SEAR  South-East Asia Region  
SFI  sustainable immunization financing  
SIA  supplementary immunization activity  
SOP  standard operating procedures  
tOPV  Trivalent Oral Polio Vaccine  
VAP  Vaccine Action Plan  
VDPV  vaccine derived polio virus  
VPD  vaccine-preventable disease  
WPV  wild polio virus
INTRODUCTION

The Seventh Meeting of the World Health Organization’s South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG) was held from 7 to 10 June 2016 in New Delhi, India.

The SEAR-ITAG is a regional technical expert group, established by the Regional Director of WHO’s South-East Asia Regional Office, for providing advice on all aspects of prevention, control, elimination and eradication of vaccine-preventable diseases (VPDs). It comprises experts from disciplines such as programme management, communicable disease/vaccine-preventable disease control, virology, epidemiology and immunization. It meets annually with the participation of national expanded programme on immunization (EPI) managers, national surveillance focal points and partners, to review progress on increasing and sustaining immunization coverage, surveillance performance, programme issues, and matters related to vaccine quality and safety. It provides guidance to Member States on ways to improve and sustain overall high-quality performance in implementing immunization programmes.

The terms of reference of ITAG as follows:

• Review Regional and Member State policies, strategies and plans for the control, elimination and/or eradication of vaccine-preventable diseases, especially for polio eradication, measles elimination, rubella/congenital rubella syndrome (CRS) control, and maternal and neonatal tetanus elimination (MNTE).
• Provide guidance on setting of regional priorities for immunization and vaccines.
• Make recommendations on the framework for development of national immunization policies as well as operational aspects of their implementation; and provide framework and approaches to periodic evaluation and strengthening of routine immunization services and systems.
• Advise Member States on appropriate choices of new vaccines and recommend optimal strategies for their introduction, including technical guidance for monitoring and impact evaluation of new vaccines once they are introduced into national immunization programmes.
• Promote and provide technical guidance for the implementation of high-quality vaccine-preventable disease surveillance, including laboratory networks for surveillance.
• Advise Member States on regulatory requirements to ensure quality and safety of vaccines used in national immunization programmes.
• Provide guidance on public private partnerships.
• Identify and advise on appropriate implementation research topics in immunization and vaccines, and review the conduct and results of such research projects.

The Meeting was chaired by Professor Gagandeep Kang. Other ITAG members present were Dr Robert Linkins, Professor Sanath Lamabadusuriya, Dr Charung Muangchana, Dr Yasho Vardhan Pradhan, Professor Mohammed Shahidullah and Professor Saw Win.
Other participants included:

- representatives from National Immunization Technical Advisory Groups (NITAGs) of Member States;
- members of the Strategic Advisory Group of Experts (SAGE) representing the Region;
- national EPI programme managers and surveillance focal points from 11 countries;
- immunization focal points from the South-East Asia Regional Office (SEARO) and WHO country offices;
- representatives from WHO headquarters;
- representatives from the United Nations Children’s Fund (UNICEF); and
- local and global partners and stakeholders.

**OBJECTIVES**

Immunization activities involve multiple stakeholders at global, regional and country levels. There is an increasing and constant need for ensuring coordination, communication and coherence between all agencies involved in the funding, implementing, regulating and developing of immunization programmes and policies. Additionally, there are time-bound immunization and disease eradication/elimination/control targets, which attract intense scrutiny of stakeholders. Thus it is essential to have regular oversight and monitoring by a regional advisory body, and to have periodic course correction. In this Region, the annual SEAR-ITAG Meeting is the mechanism that supports this role.

The primary objectives of this meeting were as follows:

1. To review the performance status of national EPI programmes in relation to disease eradication/elimination/control targets; and review the implementation of recommendations of the Sixth SEAR-ITAG Meeting 2015.
2. To seek the guidance of SEAR-ITAG in effectively addressing the following priority areas:

   - implementation of the Global Vaccine Action Plan (GVAP);
   - mid-term review of the regional flagship programme of measles elimination and rubella/CRS control by 2020;
   - implementation of the Polio Eradication and Endgame Strategic Plan 2013–2018 (outbreak response preparedness, validation of the switch from tOPV to bOPV, IPV introduction, containment of polioviruses as per Global Action Plan II and legacy planning in SEAR countries);
   - validation of MNTE during 2016;
   - vaccine quality and management;
   - introduction of new and underutilized vaccines and health system strengthening for immunization outcomes.
CONCLUSIONS AND RECOMMENDATIONS

a. National Immunization Technical Advisory Groups (NITAGs)

While emphasizing that NITAGs are independent committees whose mandate is to advise their governments towards making evidence-based immunization policy decisions, ITAG commends SEAR Member States for integrating NITAGs into the immunization-related policy-making systems in their respective countries. ITAG also congratulates Member States on establishing NITAGs in all 11 Member States.

ITAG is of the opinion that the establishment of the SEAR-NITAG voluntary network in April 2016 is a significant step towards enhancing the capacity of NITAGs in the Region. ITAG in particular notes the remarkable contribution of NITAGs in reviewing implementation of the GVAP in their respective countries through National Immunization Programmes.

ITAG recommends that:

a) The capacity of NITAGs to provide guidance on evidence-based approaches to strengthen immunization systems and services should be further enhanced by sharing country experiences, best practices and resources, as well as by peer-to-peer technical assistance through the ‘SEAR-NITAG Network’. The technical agencies and development partners should ensure sufficient support for a functional secretariat for the Network.

b) NITAGs now provide an annual report on their functioning to SEARO through their respective governments and WHO country offices. The annual reports, made in accordance with the standardized reporting format, should be reviewed at the annual SEAR-ITAG meetings. Further, individual NITAGs may consider using the WHO Collaborating Centre tool for periodic evaluation of functionality.

c) NITAGs should consider inviting representatives from their respective countries, who serve on the SAGE, SEAR-ITAG or other regional TAGs (e.g. Regional Commission for the Certification of Poliomyelitis Eradication (RCCPE) and South-East Asia Regional Verification Commission for Measles Elimination and Rubella/CRS Control (RVC) to participate in their meetings.

d) The role of NITAGs should not be limited to the consideration of recommendations for the introduction of new vaccines, but should extend to devising strategies for optimizing the use of existing vaccines and strengthening national immunization programmes.

b. South-East Asia Regional Vaccine Action Plan (SEAR-VAP)

ITAG congratulates WHO-SEARO on drafting the SEAR-VAP (2016–2020) in alignment with the goals of the GVAP (2011–2020) to reflect the joint commitment of Member States and other stakeholders towards achieving long-term collective goals in immunization in the SEA Region. ITAG recognizes the importance of defining goals, targets and priority areas for action in the SEAR-VAP, in the context of specific needs and challenges of Member States. ITAG opines that NITAGs should annually monitor and evaluate the achievement of set targets in accordance with the indicators defined by the SEAR-VAP framework.
ITAG recommends that all Member States:

a) Develop annual plans for immunization consistent with the GVAP/SEAR-VAP.
b) Establish a process to annually monitor the progress of SEAR-VAP implementation by an independent body such as their NITAG, and submit an annual progress report to the SEAR-ITAG through SEARO.

c. Equity

ITAG reiterates that equity in immunization is vital to ensuring benefits to all. ITAG believes that it is important to have country and region-specific policies/strategies in place to achieve equity in immunization. It notes the importance of improving access to marginalized populations where disease burdens tend to be disproportionately concentrated. ITAG invites Member States to focus on reaching these communities to achieve a higher degree of equity in immunization in the Region. As a means of operationalizing the outreach to these communities, ITAG recognizes the value of disaggregating data by geography, wealth and gender, generating such data where not available and streamlining specific strategies for prioritization of high-risk populations for interventions.

ITAG recommends that all Member States:

a) Endorse lessons learnt from country experiences and promote equity in its different forms, including gender, sociocultural situation and geography.
b) Must address the problem of under-immunized/unreached children and missed opportunities for vaccination (MOV) in order to achieve the GVAP goals.
c) Should prioritize targeted interventions to administrative areas with high numbers of under-immunized/un-immunized children for increasing and sustaining population immunity most efficiently.

d. Immunization Legislation

ITAG is of the opinion that Immunization Legislation is an important milestone for Member States in protecting children’s rights to quality immunization, and that it reflects a country’s political commitment to the programmatic and financial sustenance of its National Immunization Programme.

ITAG recommends that all Member States:

a) Recognize that the benefits of legislation, such as the Immunization Act of Nepal 2016, are core to achieving public health goals.
b) Consider how such legislation may be advantageous to strengthening their immunization programmes.
e. Immunization financing

ITAG is encouraged to note that Member States continuously strive to introduce new and underutilized vaccines and new technologies, while at the same time working towards achieving high and equitable immunization coverage by intensifying routine immunization and strengthening health systems. ITAG is aware that these efforts often increase the costs of national immunization programmes beyond the currently available allocations for immunization in their national budgets. It also notes the challenges posed by the differing wealth status of Member States (as reflected in the World Bank income categorization), and also by different phases of transition from Gavi support. Therefore, ITAG considers that addressing emerging needs for sustainable and predictable funding for national immunization programmes is a priority for the SEA Region.

ITAG recommends that all Member States:

a) Develop a comprehensive and sustainable immunization financing plan as part of their national immunization or any equivalent plan. These plans should be updated periodically to ensure predictable financing for:
   i. routine immunization to increase and sustain equitable immunization coverage;
   ii. introducing new and under-utilized vaccines (NUV) based on available evidence;
   iii. use of innovative technologies and strategies to promote immunization; and
   iv. strengthening health systems for immunization outcomes.

f. Polio Eradication

ITAG congratulates Member States on maintaining polio-free status of the Region for more than 5 years since the last case due to wild poliovirus (WPV) was detected in January 2011. However, it notes with concern the detection of vaccine-derived polioviruses (VDPV) from stool specimens of Acute Flaccid Paralysis (AFP) cases, as well as from sewage samples in India during the last 18 months; also an outbreak of circulating vaccine-derived poliovirus type 2 (cVDPV2) in Myanmar in 2015.

ITAG congratulates Myanmar on strong measures taken by the Ministry of Health in response to the outbreak, but remains concerned at gaps in AFP surveillance, especially in the outbreak area. It notes that the outbreak response assessment team could not conclude with certainty whether transmission of the cVDPV2 had been interrupted. It recommends urgent measures to improve the quality of AFP surveillance and to initiate environmental surveillance.

ITAG recognizes the support and guidance of donors and partners in implementing the polio eradication and endgame strategy in the Region. It acknowledges the active oversight of the National Certification Committees for Polio Eradication (NCCPE) and the Regional Certification
Commission in maintaining surveillance standards, immunization and outbreak response preparedness.

ITAG notes the continued risk of WPV spread following an importation, as well as the ongoing risk of circulating VPDV due to OPV use. ITAG is concerned about the persistently low OPV3 coverage through routine immunization (RI) in India, Indonesia, Myanmar and Timor-Leste, and notes that SIA with tOPV had been conducted in each of these Member States prior to the switch from tOPV to bOPV, to mitigate the risks of VDPV2 emergence.

ITAG is also concerned about suboptimal AFP surveillance indicators in Indonesia, Myanmar, Sri Lanka, Thailand and Democratic People’s Republic of Korea. ITAG notes the progress in expanding environmental surveillance in the Region, with the addition of sites in India and initiation of sites in Bangladesh and Indonesia. ITAG appreciates the performance of the laboratory network in support of AFP and environmental surveillance, but is concerned about performance issues in the Democratic People’s Republic of Korea laboratory.

ITAG notes the Region’s progress towards achieving the objectives of the ‘Polio Eradication and Endgame Strategic Plan 2013–2018’, including plans for IPV introduction. ITAG congratulates the ministries of health in all 11 countries for undertaking and validating the switch from tOPV to bOPV in April/May 2016 with support from WHO, UNICEF and other stakeholders. ITAG notes the challenges related to availability of sufficient IPV in the Region and measures taken to mitigate risks associated with short supply of IPV, such as the prioritization of IPV supplies to tier 1 and 2 countries. ITAG congratulates India for introducing off-label fractional dose IPV in eight states to stretch available IPV supplies. ITAG notes the progress in containment of all type 2 polioviruses as per Global Action Plan III (GAP III) in the Region despite the complexities involved in this area of work.

ITAG notes the efforts being made to ensure outbreak response preparedness in the Region, with special emphasis on preparedness for any type 2 poliovirus circulation in the post-switch period. It commends the authorization for use of mOPV2 and fractional dose IPV if an outbreak is detected.

ITAG appreciates initiation efforts in the Region to develop transition plans for polio assets in five priority countries – Bangladesh, India, Indonesia, Myanmar and Nepal – to ensure that these assets contribute to broader public health gains while sustaining polio-free status.

ITAG recommends that:

a) All Member States should continue their efforts to achieve/sustain certification-level AFP surveillance.

b) An urgent review of AFP surveillance indicators and processes at the national and subnational levels should be undertaken in Democratic People’s Republic of Korea, Indonesia, Myanmar, Sri Lanka, Thailand and Timor-Leste. Corrective actions should be identified and immediately implemented.
c) Environmental surveillance should be initiated immediately in Myanmar and in Nepal in 2016–2017. Thailand should also consider initiating environmental surveillance. Countries already conducting environmental surveillance should consider adding sites.

d) India, Indonesia, Myanmar and Timor-Leste should continue to strengthen their routine immunization programmes through the development and implementation of programme improvement plans to maximize effectiveness of IPV administered as a part of routine immunization.

e) Indonesia should ensure that IPV is introduced no later than July 2016.

f) Global Polio Eradication Initiative (GPEI) partners should regularly share information on IPV supply with all Member States, including those that self-procure the vaccine.

g) In view of the insufficient global IPV supply and the operational challenges associated with administering fractional dose of IPV, NITAGs should provide guidance to national programmes on IPV introduction strategies.

h) All Member States should ensure that their outbreak response plans are in line with GPEI protocols for response to detection of type 2 poliovirus in the post-switch period, including authorizing the emergency use of mOPV2 and IPV.

i) All Member States should ensure that containment activities are implemented as per Global Action Plan III (GAP III) within the stipulated timelines and in partnership with relevant stakeholders.

j) Ministries of health in Bangladesh, India, Indonesia, Myanmar and Nepal should develop and finalize their transition plans for polio assets by end-2016.

k) Certification activities should continue as per recommendations of the Regional Commission for Certification of Poliomyelitis Eradication (SEA-RCCPE).

g. Hepatitis B

ITAG notes the long history of immunization against hepatitis B in the SEA Region, and the achievements of Member States. However, it concludes that vaccination and control activities need to be accelerated in view of the estimated 100 million persons with chronic hepatitis B virus (HBV infection), resulting in an estimated 300 000 deaths a year from hepatocellular carcinoma (HCC), cirrhosis and other complications. HBV is highly transmissible, and newborn infants and children are at high risk. SAGE recommends two distinct but related public health interventions:

- administering a birth dose to prevent perinatal infection,
- followed by 2–3 subsequent doses giving complete protection to infants and young children.

ITAG notes the challenges of several Member States in providing timely birth-dose vaccination given the low rate of health-facility based deliveries or skilled birth attendance at home deliveries. However, the Region now has experience in overcoming this by successfully adopting innovative strategies, namely integration of birth dose with essential newborn care. While the birth dose is ideally administered within 24 hours, there are still protection benefits if given up to 7 days after birth.
ITAG considers the current global environment as very opportune for establishing a regional target for hepatitis B control through immunization, in keeping with the Global Health Sector Strategy (GHSS) for Viral Hepatitis 2016–2021 endorsed by World Health Assembly (WHA) 2016, the UN sustainable development goals (SDGs) and the GVAP. The GHSS aims at a 30% reduction of new cases of chronic viral hepatitis B by 2020, which is considered equivalent to 1% prevalence of hepatitis B virus surface antigen (HBsAg) among children.

The present environment also provides new opportunities for partner support at a stage where several Member States will be graduating from Gavi support. Experiences from other WHO regions have demonstrated how setting a control goal contributes towards heightened national commitment to hepatitis B control, and also indirectly focuses attention on strengthening routine immunization services. Furthermore, with many Member States currently developing polio legacy documents, it is an opportune time to transition polio assets and legacy to the control of hepatitis B in the Region.

ITAG recommends that Member States:

a) Conduct a systematic review of hepatitis B vaccination coverage to identify gaps and causes of under-immunization – especially with regard to birth dose – and develop/implement strategies to bring coverage to target levels.

b) Ensure that activities required for achieving hepatitis B immunization coverage goals are adequately reflected in national comprehensive multiyear plans (cMYPs) or other expanded programme on immunization (EPI) plans.

c) As the overall control of viral hepatitis incorporates a range of strategies under the responsibility of different governmental units, it is critical that hepatitis B immunization strategies are clearly reflected in national action plans with clear delineation of responsibilities. NITAGs should advocate and oversee coordination between departments to achieve immunization goals.

d) Closely coordinate with WHO and other technical partners to identify and address specific programmatic, implementation and monitoring challenges.

ITAG recommends that SEARO:

a) Establishes a regional goal for control of hepatitis B as part of the Regional Vaccine Action Plan (RVAP). The control goal should be in alignment with the Global Health Sector Strategy on Viral Hepatitis and should have a target of ≤ 1% HBsAg seroprevalence among children aged 5 years by the year 2020.

b) Develops an action plan for accelerating hepatitis B immunization towards the regional control goal. Given the diversity of epidemiological situations, the plan must be guided by a comprehensive consultation process with Member States, relevant experts and partners, and based on country needs and resource requirements.
c) Hepatitis B control action plan should be aligned with the RVAP, and consideration should also be given to the role of viral hepatitis A and E vaccination in a comprehensive hepatitis prevention strategy of national immunization programmes.

h. Maternal and Neonatal Tetanus Elimination (MNTE)

ITAG congratulates Indonesia on having achieved MNTE status as per WHO criteria in 2016, and the SEA Region on becoming the second of the six WHO regions after the European Region to achieve MNTE. ITAG considers Regional MNTE as another public health victory, proving that even access-constrained, remote and vulnerable high-risk populations can be reached.

However, sustaining MNTE requires vigilance. Member States that relied solely on routine service delivery or have reliable neonatal tetanus (NT) surveillance may face fewer challenges in sustaining MNTE as compared with Member States that employed SIAs in selected districts or in the country as a whole. Nevertheless, for all Member States, the post-elimination scenario requires addressing gaps related to access, coverage and quality of health care, and routinely reviewing district performance data. Negligence in this regard might well result in some districts, or the country as a whole, reverting to previous high MNT risk status.

As such, ITAG welcomes the WHO and UNICEF operational guidelines on ‘Sustaining Maternal and Neonatal Tetanus Elimination (MNTE) once achieved by a country’ to serve as a basis for joint action between immunization programmes, Maternal and New-born Child Health (MNCH) and surveillance managers, to address gaps that could impact a Member State’s ability to maintain MNTE.

ITAG recommends that Member States:

a) that have achieved MNTE status since the year 2000 should periodically review the performance of each district as a joint exercise by the EPI, MNCH Programme, surveillance managers and partner representatives. The review should follow WHO and UNICEF operational guidelines on ‘Sustaining Maternal and Neonatal Tetanus Elimination (MNTE) once achieved by a country’. Member States should use the assessments to implement corrective measures, taking into account the country policy/strategy, local context and feasibility.

b) that have achieved MNTE status before the year 2000 should improve and sustain sensitive neonatal tetanus (NT) surveillance in every district to maintain elimination status, as districts should remain at a reported/estimated annual NT rate below 1/1000 Live Births (LB).

c) that have not yet optimized immunization schedules for tetanus toxoid vaccination should aim at optimizing them to ensure full and early protection against tetanus with booster doses for both genders during childhood and adolescence.

ITAG recommends that SEARO:
a) develop an activity plan for monitoring/maintaining MNTE status in priority countries. This should include but not be limited to:
   i. a standard set of data to be reported, analysed and reported back to Member States for action, and
   ii. establishing a standardized format for MNTE assessment post-validation.
b) support select countries in their district-level annual performance review.

i. Measles elimination and rubella/CRS control

ITAG is encouraged by Member States’ commitment to the regional goal of measles elimination and rubella/CRS control by 2020. Nevertheless, ITAG believes that current efforts to close immunity gaps and strengthen case-based surveillance and reporting need to be intensified. To this end, ITAG will monitor a number of milestones to track progress of Member States towards reaching the measles elimination and rubella/CRS control goal by 2020.

ITAG commends Member States on progress made in providing MRCV1 and MRCV2 with high coverage through their respective routine immunization programmes. ITAG commends Member States on the formation of National Verification Committees, and SEARO on the formation of the Regional Verification Commission for Measles and Rubella. ITAG expressed concern over a resurgence of measles in Bhutan and an outbreak in Sri Lanka.

ITAG encourages exploring the option of utilizing the Region’s polio infrastructure towards the control/elimination of measles and rubella/CRS as part of the polio legacy plan. ITAG acknowledges that high vaccination coverage may necessarily not indicate the case load or interruption of transmission in a population, and thus emphasized the need to look into surveillance performance as key indicators towards verification progress. The centrality of surveillance was underlined, based on the Region’s experience with polio elimination, and thus it was emphasized that the Region should put in all resources to meet global standards of surveillance.

ITAG encourages Member States to report progress on measles elimination and rubella/CRS control to the Regional Verification Commission following review by their respective National Verification Committees.

ITAG acknowledges that the SEA Region has the world’s largest birth cohort, and that measles elimination and rubella/CRS control activities will have far-reaching implications beyond the Region and towards global progress.

ITAG recommends that:

a) All National Verification Committees (NVCs) should review and report progress on measles elimination and rubella/CRS control in their country to the Regional Verification Commission.
b) The Regional Verification Commission Secretariat in WHO SEARO should present a report on progress made towards meeting the goal of measles elimination and rubella/CRS control at the next SEAR-ITAG meeting in 2017.

c) For Member States that have introduced measles and rubella containing vaccine (MRCV), NITAGs should recommend that governments commit to rubella elimination by 2020 in keeping with the regional measles elimination goal. In Member States yet to introduce MRCV, namely India and Indonesia, efforts should continue to reach the regional rubella control goal. A 2020 target for regional rubella elimination should be set once all Member States have introduced MRCV.

ITAG recommendations related to closing the immunity gap:

a) All Member States should determine immunity profiles by birth cohort for various age groups (through desk reviews, sero-surveys or other mechanisms) and develop/implement plans to fill any gaps, including use of available opportunities for immunization, optimization of immunization schedule or implementation of supplementary immunization activities (SIAs) when appropriate.

b) All Member States should monitor two-dose measles and rubella containing vaccine (MRCV) coverage at subnational levels and implement corrective actions when needed, in line with Global Routine Immunization Strategies and Practices (GRISP).

c) India should begin to implement national wide-age range campaigns using MRCV by the end of 2016. This should be followed immediately by the introduction of MRCV in the routine immunization schedule.

d) Indonesia should begin to implement national wide-age range campaigns using MRCV by mid-2017. This should be followed immediately by the introduction of MRCV in the routine immunization schedule.

e) Democratic People's Republic of Korea should introduce MRCV in the routine immunization schedule as soon as possible, preferably no later than 2017.

f) All Member States should consider verification of measles and rubella immunity status during the school and college admission process, and also among other risk groups, and plan vaccination as necessary.

g) All Member states should consider developing subnational measles elimination and rubella control/elimination workplans, such as those that have proved to be effective in the polio eradication programme.

ITAG recommendations related to MR surveillance:

a) All Member States should conduct subnational risk assessments of measles and rubella transmission and implement risk reduction activities.

b) All Member States should revise national measles and rubella surveillance guidelines in line with the updated regional surveillance guidelines and indicators.

c) All Member States should strengthen laboratory-supported case-based surveillance for measles and rubella as per the Framework for Verification of Measles elimination and Rubella
control/elimination. India and Indonesia should continue to expand case-based surveillance following wide-age range campaigns.

d) All Member States should include linked laboratory and epidemiologic case-based data in their national measles/rubella surveillance systems, and report these data to WHO on a weekly basis, in line with current reporting requirements.

e) SEARO should update regional measles and rubella surveillance guidelines and indicators in line with the Global Framework, tailoring guidelines to account for countries at different stages of measles elimination and rubella control.

f) SEARO should encourage operational research studies on alternative sample collection (for example, dried blood spots), new vaccine delivery technologies and point-of-care diagnostics, to support Member States such as Bhutan, Maldives, Myanmar and Nepal, where conditions are challenging.

ITAG recommendations related to the MR laboratory network:

a) All laboratories in the Regional Measles and Rubella Network to institute a quality assurance process that includes routine internal auditing, and ensures an adequate supply of kits and reagents.

b) All Member States to collect adequate specimens to characterize measles and rubella genotypes. Findings should be linked with epidemiological case-based data to identify chains of transmission. Findings should be regularly shared with all stakeholders.

Among Member States with established CRS surveillance, ITAG recommends that:

a) Bangladesh and Nepal should conduct an evaluation of their CRS surveillance systems and present their findings at the next SEAR-ITAG meeting in 2017.

b) All Member States conducting CRS surveillance to report their findings to WHO on core variables as per the data dictionary on a monthly basis, as well as through Joint Reporting Form (JRF) on an annual basis.

j. Data quality

ITAG recognizes that accurate data is the cornerstone for formulating evidence-based policy, providing operational support for immunization systems and also essential for accountability at all levels.

ITAG notes that high-quality data are crucial for monitoring progress towards achieving national, regional and global goals. ITAG noted that subnational immunization coverage was not available for some Member States, nor was there a mechanism to validate such data of Member States that did provide it. ITAG notes that demographic and GIS information need to be updated by a few Member States and that case-based data collection and reporting for other VPDs like NT, diphtheria and pertussis is yet to be initiated.
ITAG appreciates the detailed review of data conducted by SEAR-IVD during 2015–2016 on immunization system performance and VPD surveillance performance indicators that were reported through the annual joint reporting form (JRF), and provided feedback to Member States on data quality and data analysis. ITAG notes that JRF data are an important source of information and performance indicators, which are used for the monitoring and accountability framework of GVAP and reporting to SAGE and WHA.

SEAR-ITAG noted the emphasis laid by SAGE on accurate data regarding prevalence and/or incidence of vaccine-preventable diseases (VPDs) and immunization system performance for evidence-based policy and operational support. ITAG reaffirmed the position of SAGE that the improvement of data quality should be one of the highest priorities for all stakeholders in the early part of the Decade of Vaccines. Likewise, data quality improvement is a Strategic Focus Area in Gavi, The Vaccine Alliance’s 2016–2020 strategy; thus, Gavi-eligible countries should meet this requirement.

ITAG recommends that Member States:

a) Conduct annual reviews to assess data quality of immunization coverage and VPD surveillance using WHO assessment tools. In-country independent resources, such as academia and professional associations, may also be used to ensure the quality of the assessments.

b) Develop, implement and monitor data quality improvement measures in response to the assessments, and develop surveillance data management systems to ensure that case-based data on Acute Flaccid Paralysis (AFP), Measles and Rubella and other priority vaccine-preventable diseases, are collected as per WHO protocols.

c) Conduct periodic national and subnational surveys to validate immunization coverage data. India and Indonesia should conduct periodic estimations of immunization coverage first at the subnational level using the WHO/UNICEF methodology for estimation of coverage.

d) Ensure that subnational level immunization coverage data are shared with SEARO.

ITAG recommends that SEARO provide technical support to Member States for:

a) Analysing and interpreting immunization data, and using the findings to develop policies and data quality improvement measures.

b) Developing data quality improvement plans and guidelines for assessing data quality.

c) Reviewing, modifying and upgrading national AFP, Measles-Rubella and VPD surveillance and immunization information systems.
k. **Vaccine quality and management**

**NRA strengthening**

ITAG recognizes that the National Regulatory Authority (NRA) of Member States is responsible for the safety, quality and efficacy of medicines/vaccines regardless of the procurement policy, that is, irrespective of whether procurement is from pre-qualified (PQ) suppliers or is locally produced.

ITAG fully realizes that some NRAs in the Region have limited resources, and therefore reminded such NRAs to use measures such as using WHO pre-qualified vaccines, learning from the experience of other NRAs and working towards regulatory convergence/harmonization under internationally accepted guidelines.

Also, ITAG encourages promotion of synergies through reliance and networking among Member States in order to further strengthen the NRA capacity.

ITAG also noted WHO’s role to regularly assess NRAs in the Region using standard WHO indicators to ensure that vaccines produced by regional manufacturers are considered for WHO pre-qualification.

ITAG reminded that the concept of functionality has now been replaced by a benchmarking approach that indicates a country NRA’s ‘maturity levels’ rather than it being adjudged ‘functional’ or ‘non-functional’.

**Related to NRA strengthening, ITAG recommends**

**1. That Member States:**

a) ensure that National Regulatory Authorities (NRAs) actively participate in addressing regulatory issues related to the vaccine life-cycle (namely manufacturing, regulation, distribution) in the newly instituted SEAR regulatory network.

b) ensure that NRAs in their respective countries enforce good distribution and storage practices, and monitor AEFI surveillance.

c) Bangladesh finalizes the new drug policy and drug act to reinforce the importance of the NRA, assure adequate resources, and continue to invest significantly in the NRA.

d) Myanmar reinforces the Food and Drug Administration (FDA) to become an independent NRA and continues to invest significantly in the NRA.

**2. That SEARO:**

a) facilitates training on the new NRA assessment tool for all concerned national staff.

b) supports the Region and Member States in implementing recommendations of the SEAR regulatory network.
c) supports the NRA in Bangladesh to achieve a maturity level that is required for the vaccine manufacturers of the country to be eligible for WHO pre-qualification functions as early as possible.

d) continues to support the Myanmar NRA in capacity-building.

e) continues to encourage and facilitate inter-country cooperation as an effective means of optimizing existing capacity and building capacity at the same time.

Vaccine availability and quality

ITAG recognizes that there is a global need to expand the number of pre-qualified vaccine manufacturers to create a more stable and competitive market. ITAG appreciates the actions taken by all stakeholders to minimize stock-outs resulting from the global shortage of BCG vaccines in 2015 and to ensure availability of sufficient buffer stocks of BCG vaccines in 2016. ITAG also understands the multiple challenges in expanding the cold-chain capacity for vaccine storage in Member States and it reminds the Gavi-eligible countries to make use of Gavi’s cold-chain optimization platform, where relevant to address this challenge. Furthermore, ITAG reiterates the importance of long-term cost-saving plans to help cold-chain expansion in view of planned new vaccine introductions in countries.

Related to vaccine availability and quality, ITAG recommends

1. That Member States:

a) especially those with limited NRA capacity, continue to exclusively use WHO pre-qualified vaccines for their immunization programmes.

b) enhance interactions between NIP managers and vaccine producers at all levels – national, regional and global – to provide manufacturers with accurate and timely information on vaccine demands and to address current vaccine shortages, especially for basic vaccines.

c) explore mechanisms of cooperation, such as the ASEAN Initiative on Vaccine Security, to promote regional access to an assured quantity and quality of vaccines at an affordable price.

2. That SEARO:

a) explore pathways to pre-qualify the cholera vaccine manufactured by Bangladesh.

I. Adverse Events Following Immunization (AEFI)

ITAG recognizes the importance of proactively engaging the media to overcome negative outfall in case of occurrence of serious AEFI. ITAG congratulates India on the initiative taken in terms of transparency and dissemination of information by publishing AEFI details on its Health Ministry’s website and urges other Member States to take similar approaches. ITAG took note of described policies with regard to compensation/hospitalization expenses for AEFI cases. ITAG congratulated Sri Lanka on its intensified AEFI surveillance through tracking and post-mortems following reports
of AEFI related to pentavalent vaccines. ITAG took note of India’s experience regarding its recently revised initiatives to improve AEFI surveillance.

Related to AEFI, ITAG recommends

1. **That Member States:**
   
a) work with academic institutions/partners to build capacity to conduct causality assessments for AEFI surveillance.

b) share AEFI data with vaccine manufacturers through the NRA and NIP to consolidate the safety profile of newly introduced vaccines.

2. **That SEARO:**
   
a) continues to support AEFI committees in AEFI investigation activities, finalizes the manual for field investigation of AEFI and facilitates its implementation at the country level.

### m. New and Underutilized Vaccines Introduction (NUVI)

**Dengue vaccine**

The ITAG took note of the progress made in the research and development of dengue vaccines. It further noted that the new WHO position paper endorsed by SAGE on dengue vaccines would be available in July 2016. However, ITAG reminded national immunization programmes and their partners that there would be many tasks to be accomplished as per SAGE recommendations, should Member States consider introducing the new dengue vaccine CYD-TDV.

**ITAG recommendations related to dengue vaccine:**

a. Member States considering the use of currently available dengue vaccine should evaluate epidemiological data such as age-specific seroprevalence rates and/or age-specific incidence rates of disease.

b. NITAG decisions with regard to introduction of the dengue vaccine should carefully consider country-level assessment, local priorities, national and subnational dengue epidemiology, predicted impact and cost-effectiveness with country-specific hospitalization rates and costs, affordability and budgetary impact.

c. Dengue vaccine introduction should be part of a comprehensive dengue-control strategy that includes effective and sustained vector control, best evidence-based clinical care for patients and robust dengue surveillance.
Other NUVI

ITAG notes that Member States have achieved significant progress in introducing new vaccines in the SEA Region. ITAG especially noted that although Bangladesh introduced the inactivated polio vaccine (IPV) and pneumococcal conjugate vaccine (PCV) simultaneously, it has faced several programmatic challenges. Also noted was the progress in introduction of rotavirus vaccine in the Region, where Thailand has introduced rotavirus vaccine as a pilot project in a single province, while India has introduced an indigenously manufactured rotavirus vaccine in four States. ITAG also congratulated Indonesia and Myanmar for preparatory activities to introduce the JE vaccine in their national immunization programmes in 2017. ITAG requested all Member States to share locally generated information about immunogenicity, efficacy, the duration of protection, safety issues of new vaccines introduced and challenges encountered.

Related to other NUVI, ITAG recommends:

a) Member States introducing multiple vaccines to children during a single visit should provide information, education and communication (IEC) to parents/guardians that in the event of non-availability of one (or more) vaccine(s) due to ‘stock-out’ or any other reason, the other available vaccine(s) should be given to the child at the prescribed time in the national schedule. The vaccine(s) that is/are missed should be administered when available.

b) Member States to educate and train health staff in the value and safety of multiple vaccines administered in a single visit.

The way forward

ITAG requests WHO-SEARO and all concerned partners to work towards setting goals in accordance with the Recommendations set forth in this report. It also directs them to prepare a progress report to be presented at the next annual ITAG meeting. Key actions for WHO-SEARO will be to:

1. provide technical assistance to Member States and facilitate implementation of ITAG recommendations in the Region

2. closely monitor the status of implementation of recommendations of ITAG and support as per the needs of the Member States.

3. strengthen research and development in the Region to generate evidence related to progress towards vaccine-preventable diseases.

4. present the implementation status and progress of the Region to the ITAG chair and members in June 2017.

ANNEX 1: MEETING AGENDA

1. Pre Meeting
- Brief overview of ITAG and NITAG operations, and review of EPI programmes by country NITAGs
- Polio eradication and endgame strategy
- Measles elimination and rubella/CRS Control
- Maternal and neonatal tetanus elimination and control of hepatitis B
- Strengthening of routine immunization services and systems, introduction of new and under-utilized vaccines and related technologies
- NRA strengthening and vaccine production in SEAR
- Effective vaccine management and social mobilization
- Health system strengthening and immunization financial sustainability
- Improving data quality

2. Opening Session of Main Meeting

3. Review of progress and achievements since last ITAG

4. Implementing Vaccine Action Plan

5. Hepatitis B situation and way forward

6. Polio eradication and endgame strategy
   - situation update
   - outbreak response
   - transition planning

7. Accelerating Measles Elimination and Rubella/CRS Control
8. Strengthening data quality for action
9. Maternal and Neonatal Tetanus Elimination

10. Strengthening vaccine quality and management

11. New and Under-Utilized Vaccine Introduction
   - developing action plans for transition of polio assets
   - closing immunity gap and strengthening surveillance for measles and rubella
ANNEX 2: LIST OF PARTICIPANTS

Member ITAG

Prof Gagandeep Kang
Chairperson ITAG, and Professor
Division of Gastrointestinal Sciences
Christian Medical College, Vellore
Tamil Nadu, India

Prof Sanath Lamabadusuriya
Emeritus Professor, Paediatrics
University of Colombo
Sri Lanka

Dr Robb Linkins
Chief, Accelerated Disease Control
Global Immunization Division
Centres for Disease Control and Prevention (USCDC)
United States of America

Dr Charung Muangchana
Director, National Vaccine Institute
Ministry of Public Health
Thailand

Dr Yasho Vardhan Pradhan
Former Director General, Department of Health Services
Ministry of Health
Nepal

Prof Shahidullah
Professor, Neonatology
Bangabandhu Sheikh Mujib Medical University
Bangladesh

Prof Saw Win
Professor/Head (Retired)
Department of Pediatrics
University of Medicine 1, Yangon
Myanmar

Ministry of Health
Bangladesh

Dr Tajul Bari
Program Manager, Expanded Programme on Immunization, MNC&AH
Directorate General of Health Services
Bangladesh

Dr Syed Rezaul Islam
Deputy Program Manager, Expanded Programme on Immunization, MNC&AH
Directorate General of Health Services
Bangladesh

Bhutan

Ms Sonam Pelden
Dy. Chief Lab. Officer, Public Health
Royal Center for Disease Control
Bhutan

Mr Tshewang Tamang
Deputy Chief Program Officer, Department of Public Health
Ministry of Health
Bhutan

Democratic People’s Republic of Korea

Dr Chol Su Kim
Senior Officer, Department of External Affairs
Ministry of Public Health
Democratic People’s Republic of Korea

India

Dr Pradeep Haldar
Deputy Commissioner, Ministry of Health and Family Welfare
Government of India
Delhi, India

Dr Mahesh Kumar Aggarwal
Deputy Commissioner, Immunization Division
Ministry of Health & Family Welfare  
Delhi, India  

Dr SK Garg  
State Immunization Officer, Medical & Health  
Government of Rajasthan  
Rajasthan, India  

Dr Narendra Kumar Sinha  
State Immunization Officer  
Expanded Programme on Immunization  
Government of Bihar  
Bihar, India  

Dr Amar Singh Thakur  
State EPI Officer, Health  
Government of Chhattisgarh  
Chhattisgarh, India  

Indonesia  

Mrs Prima Yosephine Berliana Tumiur  
EPI Manager, Directorate of Surveillance and Quarantine Health  
Ministry of Health  
Indonesia  

Mrs Ayu Rai  
Head of Section Immunization, Bali Provincial Health Office  
Indonesia  

Mrs Ann Umar  
Early Warning Section Head  
Sub Directorate Surveillance  
Ministry of Health  
Indonesia  

Mrs Mursinah  
Researcher, National Institute of Health, Research and Development  
Ministry of Health  
Indonesia  

Ms Vivi Voronika  
VPD Surveillance Coordinator, CDC  
Ministry of Health  
Indonesia  

Maldives  

Mrs Aishath Hassan  
Senior Public Health Program Officer  
Expanded Programme on Immunization  
Health Protection Agency  
Maldives  

Ms Aminath Madheeha  
Public Health Program Officer  
Health Protection Agency  
Ministry of Health  
Maldives  

Myanmar  

Dr Htar-Htar Lin  
Programme Manager, Department of Public Health  
Ministry of Health  
Myanmar  

Dr Kyaw-Soe-Moe  
Medical Officer, Expanded Programme on Immunization  
Department of Public Health  
Ministry of Health  
Myanmar  

Nepal  

Dr Rajendra Prasad Pant  
Director, Child Health Division  
Department of Health Services  
Nepal  

Dr Taranath Poudel  
Regional Director, Department of Health Services  
Western Regional Health Directorate  
Nepal  

Sri Lanka  

Dr Paba Palihawadana  
Chief Epidemiologist, Epidemiology Unit  
Ministry of Health  
Sri Lanka  

Dr Deepa Gamage
Consultant Epidemiologist, Epidemiology Unit
Ministry of Health
Sri Lanka

Thailand

Dr Pornsak Yoocharoen
Medical Officer, Expert Level, Department of Disease Control
Ministry of Public Health
Thailand

Dr Pimpa Techakamolsuk
Medical Officer, Senior Professional Level, Department of Disease Control
Ministry of Public Health
Thailand

Mrs Doungjun Chanmuang
Pharmacist, Senior Professional Level
Department of Disease Control
Ministry of Public Health
Thailand

Mr Wirat Ponlead
Public Health Technical Officer, Practitioner level
Department of Disease Control
Ministry of Public Health
Thailand

Timor-Leste

Dr Triana do Rosario Corte-Real de Oliveira
Head, Maternal and Child Health
Ministry of Health
Democratic Republic of Timor-Leste

Mrs Maria Angela Varela Niha
Head of Surveillance
Epidemiology & Surveillance Department
Ministry of Health
Democratic Republic of Timor-Leste

Mr Manuel Mausiry
EPI Programme Manager, Maternal and Child Health
Ministry of Health
Democratic Republic of Timor-Leste

RCCPE/RVC/SAGE

SAGE

Prof Jon Abramson
Chairperson SAGE, and Professor Pediatrics
Wake Forest School of Medicine
United States of America

Prof Narendra K. Arora
Member SAGE and Executive Director, Research
The INCLEN Trust International
Delhi, India

SEA-RCCPE

Dr Supamit Chunsuttiwat
Chairperson SEA-RCCPE and Senior Advisor
Department of Disease Control
Ministry of Public Health
Thailand

SEA-RVC

Prof Shahina Tabassum
Chairperson SEA-RVC and Professor & Chairman
Department of Virology
Bangabandhu Sheikh Mujib Medical University
Bangladesh

NITAG Member

Bhutan

Dr Mimi Lhamu Mynak
Chairperson, National Committee on Immunization Practices
Ministry of Health
Bhutan

Democratic People’s Republic of Korea

Dr Myong Su Pak
Director General, State Hygiene Control Board
Ministry of Public Health
Democratic People’s Republic of Korea
Indonesia

Mr Kuntjoro Harimurti
Member, Internal Medicine
The Indonesian Technical Advisory Group on Immunization
Indonesia

Maldives

Dr Nazla Luthfee
Consultant, Pediatrics
Medical Hospital
Maldives

Myanmar

Prof Soe-Lwin Nyein
Director General, Department of Public Health
Ministry of Health
Myanmar

Nepal

Dr Ramesh Kant Adhikari
Chairman, National Committee on Immunization Practices
Ministry of Health
Nepal

Thailand

Dr Sombat Thanprasertsuk
Senior Expert in Prevention Medicine
Department of Disease Control
Ministry of Public Health
Thailand

Timor-Leste

Ms Virna Martins Sam
Chairperson, National Immunization Technical Advisory Group
Ministry of Health
Democratic Republic of Timor-Leste

Donors and Partners

BMGF

Dr Raj Shankar Ghosh
Deputy Director, Vaccine Delivery & Infectious Diseases
Bill & Melinda Gates Foundation
Delhi, India

CDC

Dr Kimberley Fox
Chief, Immunization Systems Branch
Global Immunization Division
CDC
United States of America

Dr Rania Tohme
Team Lead, Global Immunization Division
CDC
United States of America

Dr Emma Lebo
Epidemiologist, Global Immunization Division
CDC
United States of America

Gavi, The Vaccine Alliance

Mr Dirk Gehl
Senior Country Officer, Country Programmes
Gavi
Switzerland

Ms Carol Szeto
Senior Country Manager - India, Country Support
Gavi
Switzerland

Mr Par Eriksson
Consultant, South-East Asia Programme
Delivery Team
Gavi
Switzerland

Mr Nicolas Theopold
Strategy Manager
Gavi
Switzerland

IAP

Dr Pramod Jog
President,
Indian Academy of Pediatrics (IAP)
Mumbai, India

JSI

Ms. Lora Shimp
Senior Immunization Technical Officer
John Snow, Inc (JSI)
United States of America

Dr Bhrigu Kapuria
Senior Immunization Advisor, Immunization
JSI
Delhi, India

PATH

Dr Bill Letson
Scientific Advisor for Japanese Encephalitis
PATH
United States of America

Dr Shalini Khare
Senior Program Officer
JE Vaccination and Sustainability Project
PATH
Delhi, India

PHFI

Dr Jyoti Joshi
Deputy Director
Immunization Technical Support Unit
Public Health Foundation of India
Delhi, India

Dr Vineeth Varanasi
Associate Advisor
Immunization Technical Advisory Group
Public Health Foundation of India
Delhi, India

Rotary International

Mr Deepak Kapur
Chairman, Rotary International India
PolioPlus Committee
New Delhi, India

Mr Lokesh Gupta
Manager, Rotary International India
PolioPlus Committee

New Delhi, India

Sabin Vaccine Institute

Dr Mike McQuestion
Director, Sustainable Immunization Financing
Sabin Vaccine Institute
United States of America

Dr Devendra Gnawali
Senior Program Officer
Sustainable Immunization Financing Program
Sabin Vaccine Institute
United States of America

IVAC

Ms Lois Privor-Dumm
Director, Policy, Advocacy & Communications
International Vaccine Access Centre
IVAC/ Johns Hopkins University
United States of America

UNICEF

HQ

Dr Robin Nandy
Principal Advisor & Chief of Immunization,
Health Section, UNICEF
United States of America

Mr Richard Duncan
Senior Immunization Specialist,
Health Section, UNICEF
United States of America

Supply Division

Mrs Ann Egede Ottosen
Senior Manager, Vaccine Centre
UNICEF Supply Division
Denmark

Mr Hans Christiansen
Contracts Manager, Vaccine Centre
UNICEF
Denmark

EAPRO
Dr Xiaojun Wang
Immunization Specialist,
Young Child Survival and Development
UNICEF Regional Office for East Asia and the Pacific
Thailand

ROSA

Dr Yin Yin Aung
Regional Immunization Specialist, Health
UNICEF Regional Office for South Asia
Nepal

Dr Andreas Hasman
Regional Immunization Specialist, Health
UNICEF Regional Office for South Asia

Dr Srihari Dutta
Regional Immunization Specialist, Health
UNICEF Regional Office for South Asia

India

Dr Yaron Wolman
Chief, Health Section
UNICEF
New Delhi, India

Ms Nicole Deutsch
Chief, Polio
UNICEF
New Delhi, India

Dr Satish Gupta
Health Specialist, Immunization
UNICEF
Delhi, India

Indonesia

Ms Kenny Peetosutan
Health Specialist, Immunization
Child Survival and Development
UNICEF
Indonesia

Myanmar

Ms Penelope Campbell
Chief, Young Child Survival and Development
UNICEF
Myanmar

Nepal

Dr Hendrikus Raaijmakers
Chief, Health
UNICEF
Nepal

Timor-Leste

Dr Hemlal Sharma
Chief, Health and Nutrition System
UNICEF
Democratic Republic of Timor-Leste

Observers

GlaxoSmithKline

Dr Anil Dutta
Vice President-Clinical/Medical, R & D
GSK Vaccines
Belgium

Dr Sanjay Gandhi
Vice President, South Asia (Vaccines)
Clinical R&D, Medical Affairs & Public Health
GSK
Maharashtra, India

Others

Ms Jyotsna Ghoshal
Senior Director, Corporate Affairs
MSD Pharmaceuticals Pvt. Ltd.
Haryana, India

Dr Saurabh Sharma
Director, Immunization Policy & Advocacy
Sanofi Pasteur India Pvt. Ltd.
New Delhi, India

Mr Samir Deb
Senior Advisor, Public Affairs (Vaccines)  
Sanofi Pasteur India Pvt. Ltd.  
New Delhi, India

Dr Ranjana Kumar  
Independent  
Observer  
Delhi, India

Serum Institute of India

Mr S.K. Bahl  
Director, Business and Regulatory Affairs  
Serum Institute of India Pvt. Ltd.  
New Delhi, India

IAIM

Dr Shyam Raj Uperti  
Governing Council Member  
International Association of Immunization Managers (IAIM)  
Nepal

WHO

WCO BANGLADESH

Dr Jayantha Liyanage  
Medical Officer EPI  
Immunization and Vaccine Development  
World Health Organization  
Bangladesh

Dr Stephen Chacko  
Medical Officer, Immunization Systems Strengthening  
Immunization and Vaccine Development  
World Health Organization  
Bangladesh

WCO Democratic People’s Republic of Korea

Dr Zobaidul Haque Khan  
Technical Officer (Epidemiology),  
World Health Organization  
Democratic People’s Republic of Korea

WCO India

Dr Pankaj Bhatnagar

National Professional Officer (Immunization), Polio  
World Health Organization  
Delhi, India

Dr Balwinder Singh  
National Professional Officer (Routine Immunization)  
Polio  
World Health Organization  
Delhi, India

WCO Indonesia

Dr Vinod Kumar Bura  
Medical Officer, Immunization and Vaccine Development  
World Health Organization  
Indonesia

Mrs Niprida Mardin  
National Professional Officer  
Immunization and Vaccine Development  
World Health Organization  
Indonesia

WCO Maldives

Dr Shushil Pant  
Medical Officer, Public Health  
World Health Organization  
Maldives

WCO Myanmar

Dr Rajendra Bohara  
Technical Officer, EPI  
Immunization and Vaccine Development  
World Health Organization  
Myanmar

WCO Nepal

Dr Ganga Ram Choudhary  
Team Lead, IPD  
World Health Organization  
Nepal

WCO Sri Lanka

Dr Navaratnasingam Janakan  
National Professional Officer, CDC
Ms Aree Moungsokjareoun  
EPI focal point, WCO Thailand  
World Health Organization  
Thailand

Dr Sudath Peiris  
Technical Officer, Immunization and Vaccine Development  
World Health Organization  
Democratic Republic of Timor-Leste

Mr Mateus Cunha  
NPO/GAVI/HSS, Immunization  
World Health Organization  
Democratic Republic of Timor-Leste

WHO HQ

Mr Michel Zaffran  
Director, Polio Eradication  
World Health Organization  
Switzerland

Dr Joachim Hombach  
Senior Adviser, Initiative for Vaccine Research  
World Health Organization  
Switzerland

Dr Philippe Duclos  
Senior Health Adviser, Immunization, Vaccines and Biologicals  
World Health Organization  
Switzerland

Dr Patrick Zuber  
Group Lead, EMP  
Global Vaccine Safety  
Switzerland

Dr Robert Perry  
Medical Officer, IVB  
World Health Organization  
Switzerland

Ms Ebru Ekeman  
POL, World Health Organization  
Switzerland

WHO SEARO

Dr Pem Namgyal  
Director, Department of Family Health, Gender and Life Course  
World Health Organization  
Delhi, India

Dr Nihal Abeysinghe  
Actg. Coordinator, Immunization and Vaccine Development  
World Health Organization  
Delhi, India

Dr Sunil Bahl  
Regional Adviser, Immunization and Vaccine Development  
World Health Organization  
Delhi, India

Dr Sigrun Roesel  
Technical Officer, Immunization and Vaccine Development  
World Health Organization  
Delhi, India

Ms Sirima Pattamadilok  
Scientist, Immunization and Vaccine Development  
World Health Organization  
Delhi, India

Ms Uttara Aggarwal  
Technical Officer, Immunization and Vaccine Development  
World Health Organization  
New Delhi, India

Dr Martin Eisenhawer  
Scientist, Immunization and Vaccine Development  
World Health Organization  
New Delhi, India

Dr Pushpa Ranjan Wijesinghe  
Medical Officer, Immunization and Vaccine
Dr Sudhir Khanal
Medical Officer, Immunization and Vaccine Development
World Health Organization
Delhi, India

Mr Tika Ram Sedai
Technical Officer, Immunization and Vaccine Development
World Health Organization
Delhi, India

Dr Aarti Garg
Junior Professional for Public Health
Immunization and Vaccine Development
World Health
Delhi, India

Mr Deepak Dhongde
Data Management Associate, Immunization and Vaccine Development
World Health Organization
Delhi, India

Mr Poonam Mehra
Associate, Immunization and Vaccine Development
World Health Organization
Delhi, India

Ms Seema Kapoor
Executive Assistant, Immunization and Vaccine Development
World Health Organization
New Delhi, India

Mr Rajiv Maken
Executive Assistant, Immunization and Vaccine Development
World Health Organization
Delhi, India

Mr Ravinder Negi
Team Assistant, Immunization and Vaccine Development
World Health Organization
Delhi, India

Ms Chitra Salil
Assistant, Immunization and Vaccine Development
World Health Organization
New Delhi, India

Ms Poonam Sharma
Team Assistant, Immunization and Vaccine Development
World Health Organization
New Delhi, India

Ms Malu Adlakha
Supply Assistant, Immunization and Vaccine Development
World Health Organization
New Delhi, India